POTENTIAL THERAPEUTIC USES OF NEUREGULIN-2

Information

  • Research Project
  • 6072197
  • ApplicationId
    6072197
  • Core Project Number
    R43NS039709
  • Full Project Number
    1R43NS039709-01
  • Serial Number
    39709
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/16/2000 - 24 years ago
  • Project End Date
    10/15/2000 - 24 years ago
  • Program Officer Name
    NICHOLS, PAUL L
  • Budget Start Date
    5/16/2000 - 24 years ago
  • Budget End Date
    10/15/2000 - 24 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    5/16/2000 - 24 years ago

POTENTIAL THERAPEUTIC USES OF NEUREGULIN-2

Neuregulin(NRG) proteins have interesting, diverse biological properties, and offer opportunities to develop novel therapies. One of the long-term objectives of discovery research on NRG signalling is to identify potential clinical indications. Ultimately, recombinant human NRGs may be put to use as therapies. The overall goal of the proposed research is to discover potential therapeutic uses for a nrg-2 protein by following the strategy that was used for recombinant human glial growth factor 2(rhGGF2).That secreted isoform of nrg-1 was produced in mammalian cells, then used to explore responses in various biological systems. The work led to the discovery of nrg-1 functions and bioactivities that might be relevant to specific disorders, and thereby indicate potential therapeutic uses for rhGGF2. Now the focus is on identification of potential therapeutic uses for nrg-2. From preliminary work, human nrg-2 cDNAs were identified and used to construct an expression vector encoding a full-length, secreted human nrg-2 protein. Further, antisera and a standard bioassay have been developed to monitor expression and purification. Three Specific Aims are proposed in Phase 1 to demonstrate the feasibility of this approach. Aims 1 and 2 are directed at expressing and purifying moderate quantities of recombinant human nrg-2 protein to enable testing for specific bioactivities in selected in vitro assays (aim 3). PROPOSED COMMERCIAL APPLICATIONS: A large number of disorders of the nervous system still are without effective treatment. Recombinant human growth factors, due to their potent trophic and regenerative actions on damaged tissues, represent a novel approach to the discovery and development of drugs for treatment of neurological and degenerative disorders. Neuregulins are essential for normal development and have been shown to be efficacious in several animal models of disease. Thus NRGs present multiple opportunities to identify novel treatments for nervous system disorders. Accordingly, the commercial potential is large.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R43
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    853
  • Ed Inst. Type
  • Funding ICs
    NINDS:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CAMBRIDGE NEUROSCIENCE
  • Organization Department
  • Organization DUNS
  • Organization City
    NORWOOD
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02062
  • Organization District
    UNITED STATES